Upgrade to SI Premium - Free Trial

Biogen (BIIB) PT Lowered to $340 at Goldman Sachs

April 25, 2024 6:21 AM
Goldman Sachs analyst Salveen Richter lowered the price target on Biogen (NASDAQ: BIIB) to $340.00 (from $393.00) while maintaining a Buy rating.

Categories

Analyst PT Change

Next Articles